Pulse Biosciences präsentiert erfolgreiche Studiendaten zum nPulse Cardiac Catheter System bei Vorhofflimmern

Reuters

Feb 06

<a href="https://laohu8.com/S/PLSE">Pulse Biosciences</a> präsentiert erfolgreiche Studiendaten zum nPulse Cardiac Catheter System bei Vorhofflimmern

Pulse Biosciences Inc. hat neue klinische Daten aus der First-in-Human-Feasibility-Studie zum nPulse™ Cardiac Catheter System vorgestellt. Die Ergebnisse wurden auf dem 31. Annual AF Symposium 2026 in Boston präsentiert. In der Studie wurden bislang 165 Patienten mit Vorhofflimmern in Europa behandelt. Die Daten zeigen eine 100-prozentige prozedurale Erfolgsrate bei auswertbaren Patienten nach sechs Monaten. Die Sicherheit und Wirksamkeit des Systems wird weiterhin im Rahmen der laufenden Studie überprüft.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260205902371) on February 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2609453537"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609453537\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609453537?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 08:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609453537","market":"nz","top_or_hot":-1,"title":"Pulse Biosciences präsentiert erfolgreiche Studiendaten zum nPulse Cardiac Catheter System bei Vorhofflimmern","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PLSE\">Pulse Biosciences</a> präsentiert erfolgreiche Studiendaten zum nPulse Cardiac Catheter System bei Vorhofflimmern\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pulse Biosciences Inc. hat neue klinische Daten aus der First-in-Human-Feasibility-Studie zum nPulse™ Cardiac Catheter System vorgestellt. Die Ergebnisse wurden auf dem 31. Annual AF Symposium 2026 in Boston präsentiert. In der Studie wurden bislang 165 Patienten mit Vorhofflimmern in Europa behandelt. Die Daten zeigen eine 100-prozentige prozedurale Erfolgsrate bei auswertbaren Patienten nach sechs Monaten. Die Sicherheit und Wirksamkeit des Systems wird weiterhin im Rahmen der laufenden Studie überprüft.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260205902371) on February 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pulse Biosciences präsentiert erfolgreiche Studiendaten zum nPulse Cardiac Catheter System bei Vorhofflimmern</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPulse Biosciences präsentiert erfolgreiche Studiendaten zum nPulse Cardiac Catheter System bei Vorhofflimmern\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-06 08:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PLSE\">Pulse Biosciences</a> präsentiert erfolgreiche Studiendaten zum nPulse Cardiac Catheter System bei Vorhofflimmern\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pulse Biosciences Inc. hat neue klinische Daten aus der First-in-Human-Feasibility-Studie zum nPulse™ Cardiac Catheter System vorgestellt. Die Ergebnisse wurden auf dem 31. Annual AF Symposium 2026 in Boston präsentiert. In der Studie wurden bislang 165 Patienten mit Vorhofflimmern in Europa behandelt. Die Daten zeigen eine 100-prozentige prozedurale Erfolgsrate bei auswertbaren Patienten nach sechs Monaten. Die Sicherheit und Wirksamkeit des Systems wird weiterhin im Rahmen der laufenden Studie überprüft.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260205902371) on February 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PLSE","symbol_name":"Pulse Biosciences, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL3ZsHSQ:1","article_id":"2609453537","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609453537","pubTimestamp":1770336017,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pulse Biosciences Inc. hat neue klinische Daten aus der First-in-Human-Feasibility-Studie zum nPulse Cardiac Catheter System vorgestellt. Die Ergebnisse wurden auf dem 31. Annual AF Symposium 2026 in Boston prsentiert. In der Studie wurden bislang 165 Patienten mit Vorhofflimmern in Europa behandelt. Die Daten zeigen eine 100-prozentige prozedurale Erfolgsrate bei auswertbaren Patienten nach sechs Monaten. Die Sicherheit und Wirksamkeit des Systems wird weiterhin im Rahmen der laufenden Studie überprüft.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire  on February 06, 2026, and is solely responsible for the information contained ther","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PLSE":"Pulse Biosciences, Inc.","BK4082":"医疗保健设备"},"translate_title":"Pulse Biosciences展示nPulse心导管系统治疗心房颤动的成功研究数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLSE":0.9},"content_text":"Pulse Biosciences präsentiert erfolgreiche Studiendaten zum nPulse Cardiac Catheter System bei Vorhofflimmern\n    \n\n        Pulse Biosciences Inc. hat neue klinische Daten aus der First-in-Human-Feasibility-Studie zum nPulse™ Cardiac Catheter System vorgestellt. Die Ergebnisse wurden auf dem 31. Annual AF Symposium 2026 in Boston präsentiert. In der Studie wurden bislang 165 Patienten mit Vorhofflimmern in Europa behandelt. Die Daten zeigen eine 100-prozentige prozedurale Erfolgsrate bei auswertbaren Patienten nach sechs Monaten. Die Sicherheit und Wirksamkeit des Systems wird weiterhin im Rahmen der laufenden Studie überprüft.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260205902371) on February 06, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}